" class="no-js "lang="en-US"> SomaLogic - Medtech Alert
Tuesday, April 16, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
SomaLogic | Pharmtech Focus

SomaLogic

About SomaLogic

SomaLogic

Revolutionizing Proteomics To Transform Healthcare

SomaLogic was founded in 2000 with the goal of improving the well-being and quality of life of every individual by transforming how diseases were detected and diagnosed. Building on the previous decade of aptamer research, SomaLogic scientists have developed a new proteomics technology that overcomes the significant challenges of current technologies, and which has multiple applications across the biological and medical sciences.

Our mission is to leverage our proprietary technology to discover, develop and commercialize revolutionary new life science research tools and breakthrough clinical diagnostic products that will transform healthcare.

If you would like to learn more about SomaLogic, visit www.SomaLogic.com, follow us on www.twitter.com/SomaLogic (@SomaLogic) or contact us at information@somalogic.com or 303-625-9000.

Related Story

Industry News

 Somalogic Acquires DNA Nanotechnology Leader Palamedrix to Develop the Next-generation SomaScan® Assay | Pharmtech Focus

Somalogic Acquires DNA Nanotechnology Leader Palamedrix to Develop the Next-generation SomaScan® Assay

July 27 2022

SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced it entered into […]

Diseases

 SomaLogic Announces License Agreement with OncoHost for the Development of Precision Cancer Diagnostics | Pharmtech Focus

SomaLogic Announces License Agreement with OncoHost for the Development of Precision Cancer Diagnostics

June 14 2022

SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced it has signed a […]

Cardiovascular

 Major Journal Publishes Landmark Proteomics Study Demonstrating Development of an Unprecedented New Clinical Cardiovascular Risk Test | Pharmtech Focus

Major Journal Publishes Landmark Proteomics Study Demonstrating Development of an Unprecedented New Clinical Cardiovascular Risk Test

April 13 2022

In one of the largest proteomic studies ever conducted and published April 6 in the […]

Diseases

 SomaLogic to Provide 210 Million Protein Measurements to EPIC Researchers to Better Understand and Predict Cancer Development | Pharmtech Focus

SomaLogic to Provide 210 Million Protein Measurements to EPIC Researchers to Better Understand and Predict Cancer Development

March 22 2022

SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that the company will […]

Appointments

 SomaLogic Announces Appointment of Adam Taich as Chief Business Officer | Pharmtech Focus

SomaLogic Announces Appointment of Adam Taich as Chief Business Officer

January 11 2022

SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that Adam Taich has […]

Industry News

 SomaLogic Announces Exclusive Partnership with Illumina to Develop Sequencing-based Proteomic Solutions | Pharmtech Focus

SomaLogic Announces Exclusive Partnership with Illumina to Develop Sequencing-based Proteomic Solutions

January 6 2022

SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a worldwide strategic collaboration […]

Clinical Trials

 SomaLogic Announces Strategic Collaboration with University Hospitals Cleveland Medical Center to Treat Diabetic Patients at High Risk of Cardiovascular Disease | Pharmtech Focus

SomaLogic Announces Strategic Collaboration with University Hospitals Cleveland Medical Center to Treat Diabetic Patients at High Risk of Cardiovascular Disease

November 1 2021

SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a strategic collaboration with […]

Appointments

 SomaLogic Expands Leadership Team with New Positions to Drive Commercial Success | Pharmtech Focus

SomaLogic Expands Leadership Team with New Positions to Drive Commercial Success

September 1 2021

CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, a leader in AI data-driven proteomics technology, […]

Appointments

 SomaLogic Announces Appointment of Shaun Blakeman as Chief Financial Officer | Pharmtech Focus

SomaLogic Announces Appointment of Shaun Blakeman as Chief Financial Officer

August 3 2021

CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, a leader in AI-data driven proteomics technology, […]